Cardio Diagnostics Holdings, Aimil to Introduce Cardiovascular Epigenetic Technologies to India

Cardio Diagnostics Holdings Inc. is entering into a supply and distribution agreement with Aimil Ltd. to provide patients access to the former firm’s diagnostic test for coronary heart disease (CHD).
 
Cardiovascular disease (CVD) remains the leading cause of death in India, with the nation facing alarmingly high incidences. According to the Global Burden of Disease study by the Institute for Health Metrics and Evaluation, the age-standardized CVD death rate in India is 282 deaths per 100,000 people, which is markedly higher than the global average of 233 deaths per 100,000 people. Studies have reported that Indian patients develop heart disease nearly a decade earlier than their European counterparts, with approximately 62% of heart disease related deaths among Indians being premature. This strategic venture between Cardio Diagnostics and Aimil seeks to address the growing prevalence of heart disease in India by introducing Cardio Diagnostics’ clinical test, PrecisionCHD, for detecting and personalizing CHD management.

“Heart disease is a global problem and Cardio Diagnostics’ expansion to India underscores our commitment to combat heart disease globally. We are thrilled to partner with Aimil on our first international expansion,” Cardio Diagnostics Co-Founder/CEO Meesha Dogan Ph.D., said. “This expansion is possible because Cardio Diagnostics’ clinical tests are developed with scalability in mind with respect to operations and costs, enabling deployment across diverse healthcare landscapes worldwide, to play a transformative role in mitigating heart disease globally.”
 
The first phase of this collaboration will focus on pre-marketing, laying the groundwork for a successful product introduction to Aimil’s healthcare network. Cardio Diagnostics and Aimil intend to further expand the supply and distribution agreement after a successful phase one to ensure that customers in India have consistent and reliable access to Cardio Diagnostics’ diagnostic test. With Cardio Diagnostics’ PrecisionCHD test, there is a significant opportunity to reduce the burden of CHD across India. Unlike current tests to diagnose CHD such as a stress test and CCTA, PrecisionCHD does not require costly infrastructure nor exposing a patient to radiation or kidney-damaging contrast dye. PrecisionCHD only requires a simple blood draw from the patient, allowing for this test to be deployed at scale in both urban and rural settings. 
 
“We are excited to collaborate with Cardio Diagnostics to introduce the first epigenetics-based heart disease diagnostic technology to India. Aimil is committed to empowering our customers, partners, and the healthcare community in India with solutions to tackle heart disease,” Aimil Executive Director Dr. Mallika Kapur stated.
 
Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The company was formed to further develop and commercialize clinical tests by leveraging a proprietary artificial intelligence (AI)-driven Integrated genetic-epigenetic engine for cardiovascular disease to help improve prevent, detect, and treat cardiovascular disease. 
 
Aimil was founded in 1932, with a mission to bring leading edge technologies to India. With 14 sales and service offices across India, more than 1,000 employees, NABL certified testing and calibration laboratories, and manufacturing, R&D and software development capability, Aimil offers value-added distribution to overseas companies that want to expand professionally in India.